KRAS and colorectal carcinoma: Across a CRC panel that included SNU-C5/WT and its 5-fluorouracil- and oxaliplatin-resistant derivatives, HT-29 (KRAS-wild-type), and HCT-8 and LoVo (KRAS-mutant), co-immunoprecipitation showed that PrP<sup>C</sup> forms complexes with the 37/67 kDa laminin receptor (RPSA), with PrP<sup>C</sup>-RPSA association particularly increased in KRAS-mutant HCT-8 and LoVo cells.